# Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor

> **NCT00356525** · PHASE2 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 41 (actual)

## Conditions studied

- Lung Neoplasms

## Interventions

- **DRUG:** pemetrexed
- **DRUG:** gemcitabine
- **DRUG:** carboplatin
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT00356525
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-09
- **Primary completion:** 2008-06
- **Final completion:** 2009-04
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** Stopped early due to low enrollment
- **Last updated:** 2010-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00356525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00356525, "Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00356525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*